Biopharmaceuticals

— Latest update: July 2022 —

With the world’s highest proportion of the elderly (nearly 30% in 2020), the number of patients with cancer and other diseases is expected to increase in Japan. It is the third largest pharmaceutical market in the world, and the biologically active substances (biopharmaceuticals) are considered to be the driving force behind innovation in this industry. In 2021, the Japanese biopharmaceutical market value was estimated at 2,1 trillion yen. Even though the pharmaceutical market growth is projected to be negative, the biopharmaceutical sector is expected to grow.

EU-Japan Centre, The Biopharmaceuticals sector in Japan, 2019
EU-Japan Centre, Latest trends in biotechnology research in Japan, 2021
JETRO, Life Science Report, 2022
International Trade Administration, Japan-Pharmaceuticals, 2022

> For more information about the Japanese pharmaceutical market, laws, and regulations, click here

Table of Contents

• Collaborative Opportunities
• Regenerative Medicine
• Gene Therapy
• Blood Substitutes
• Vaccines
• Antibody and Peptide-based Drugs
• Biosimilars
• Expert Reports & Webinars
• Annual Report
• Further Reading
• Relevant Organisations and Trade Fairs